BOTHELL, Wash., June 11, 2018 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), the leading
developer, manufacturer and marketer of proprietary clinical-grade biopreservation media, today announced that it is set to join
the Russell Microcap® Index at the conclusion of the Russell US Indexes annual reconstitution, effective after
the US market opens on June 25th, according to a preliminary list of additions posted June 8th.
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in
the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell US Indexes primarily by
objective, market-capitalization rankings and style attributes. Russell US Indexes are widely used by investment managers and
institutional investors as the basis for index funds and as benchmarks for active investment strategies. Approximately
$9 trillion in assets are benchmarked against Russell US Indexes. Russell US Indexes are part of
FTSE Russell, a leading global index provider.
For more information on the Russell Microcap® Index and the Russell US Indexes reconstitution, go to the
"Russell Reconstitution" section on the FTSE Russell website.
About BioLife Solutions
BioLife Solutions is the leading developer, manufacturer and supplier of proprietary, clinical-grade biopreservation media for
cells and tissues. Our HypoThermosol ® hypothermic storage and CryoStor ® cryopreservation freeze
media are highly valued in the regenerative medicine, biobanking and drug discovery markets. These novel biopreservation media
products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death;
offering commercial companies and clinical researchers significant improvement in shelf life and post-preservation viability and
function. For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.
Except for historical information contained herein, this press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited
to, statements concerning the company's anticipated business and operations, guidance for financial results in 2018, including
achieving GAAP operating profit, EBITDA, adjusted EBITDA and cash flow from operations, the potential utility of and market for
its products and services, potential revenue growth and market expansion, regulatory approvals and/or commercial manufacturing of
our customers' products, and potential customer revenue, and future redemptions of Series A Redeemable Preferred stock. All
statements other than statements of historical fact are statements that could be deemed forward-looking statements. These
statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and
assumptions that could cause actual results to differ materially from those described in the forward-looking statements,
including among other things, uncertainty regarding market adoption of products; uncertainty regarding third-party market
projections; market volatility; competition; litigation; and those other factors described in our risk factors set forth in our
filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events
or circumstances occurring after the date hereof, other than as may be required by applicable law.
Media & Investor Relations
Roderick de Greef
Chief Financial Officer
(425) 686-6003
rdegreef@biolifesolutions.com
View original content with multimedia:http://www.prnewswire.com/news-releases/biolife-solutions-to-join-russell-microcap-index-300664126.html
SOURCE BioLife Solutions, Inc.